

Hematologic malignancies (HMs) represent a significant portion of the global cancer burden. Despite various standard treatments, primary resistance, relapse, and adverse effects have led to treatment failure in many patients
This white paper focuses on in vivo-engineered T-cell therapy for three major HM subtypes of the B lineage: acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). In vivo CAR-T therapies represent a paradigm shift in immuno-oncology, offering a promising approach toward scalable, accessible, and cost-effective treatment for HMs. In vivo CAR-T platforms eliminate the need for complex cell harvesting and manufacturing, potentially broadening patient access and reducing logistical burdens.
Download the full white paper to explore in vivo CAR T innovation, the opportunities offered, key regulatory frameworks, what this innovation could mean for the future of scalable and accessible advanced therapeutics.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.